Vigil Neuroscience

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

–Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers–

Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at three upcoming investor conferences. Details are as follows:

Vigil Neuroscience to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline results from its ongoing Phase 1 clinical trial of VGL101, its lead product candidate, in healthy volunteers. These interim data support the initiation of a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) with a 20 mg/kg dose.

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VGL101 for the treatment of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). VGL101, Vigil's lead product candidate, is a monoclonal antibody TREM2 agonist currently being evaluated in a Phase 1 trial in healthy volunteers.

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Akero Therapeutics Inc

Astria Therapeutics

HeartBeam

ContraFect

Humanigen

Otonomy

Rhythm Pharmaceuticals

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

Cricut

Janux Therapeutics

Loop Industries

Omega Flex

Olink Holding AB

Red Violet

Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a reactionary panic.

7 Short-Squeeze Stocks to Buy for Contrarian Investors

The consensus price target hints at a 121.3% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2022 Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, at 4:50 p.m. ET.

Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference

The consensus price target hints at a 132.7% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%

The mean of analysts' price targets for Vigil Neuroscience, Inc. (VIGL) points to a 166.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 7,293,084 shares of its common stock (“Common Stock”) at a price of $7.30 per share and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to an aggregate of 2,980,889 shares of common stock at a purchase price of $7.2999 per pre-funded warrant, through a private investment in public equity (“PIPE”) financing. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The prices of Common Stock and Pre-Funded Warrants do not include any discounts.

Vigil Neuroscience Announces $75 Million Private Placement Financing

– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia –

Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 9, 2022 at 11:30 a.m. ET.

Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented two posters at the Alzheimer's Association International Conference (AAIC) in San Diego.

Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022

Biogen

CinCor Pharma

CRISPR Therapeutics

Emergent BioSolutions

Global Blood Therapeutics

Harmony Biosciences Holdings

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.

7 No-Brainer Biotech Stocks to Add to Your Buy List

Bionomics Ltd

Esports Entertainment Group

Kiromic Biopharma

Lesaka Technologies Inc

PureCycle Technologies

PMV Pharmaceuticals

Entrada Therapeutics

We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.

Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday

- Received approval from the Human Research Ethics Committee in Australia to initiate a Phase 1 trial of VGL101 in healthy volunteers at doses above 20 mg/kg -

Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia

- Presented key findings enhancing clinical understanding of ALSP at the 2022 American Academy of Neurology Annual Meeting -

Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights

Amylyx Pharmaceuticals

Games & Esports Experience Acquisition Corp

Hour Loop

Modiv

Smart for Life Inc

Talon 1 Acquisition Corp

Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes.

These Were the 10 Worst Performing IPOs in Q1 2022

- Completed successful initial public offering, raising $98 million in gross proceeds -

Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 CNS Days virtual conference on Monday, March 28, 2022 at 9:45 a.m. ET.

Vigil Neuroscience to Present at Stifel 2022 CNS Days

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced two poster presentations at the 2022 American Academy of Neurology (AAN) Annual Meeting. All posters will be presented electronically.

Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting

Should you add these stocks to your portfolio?

New Year, Fresh Stocks: 3 IPOs That Joined the Market in January

CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the closing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds of the offering were $98 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Vigil Neuroscience has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the initial public offering price less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on January 7, 2022 under the symbol “VIGL.” All shares in the offering were offered by Vigil Neuroscience.

Vigil Neuroscience Announces Closing of Initial Public Offering

The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Four SPACs went public led by Sagansky and Sloan's Screaming Eagle Acquisition, which raised $750 million.

U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week

News for Vigil Neuroscience Stock (VIGL)